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Summary  
Interleukin-1 receptor type I (IL-1RI) expression i cultured rabbit articular chondrocytes (RAC) was studied by reverse 
transcription-polymerase chain reaction (RT-PCR). A cDNA probe specific for the rabbit IL-1RI gene was constructed 
using primers derived from the sequence data of the human, murine and chick receptors. Transforming growth factor-ill 
(TGFfl-1) was shown to transiently increase the level of expected 900-bp PCR product at 1 h of incubation and decrease 
the expression at 48 and 72 h with no effect at 24 h. In receptor binding assays using [I~I]-IL-I~, TGFfl decreased IL-1R 
bioactivity at all time points. These results uggest that TGFfl-induced own-regulation f IL-1 RI could be responsible 
for its ability to antagonize the effect of IL-1 and that TGFfl may have a role in the repair of articular cartilage. 
Key words: Reverse transcription-polymerase chain reaction, Transforming growth factor-fl, Interleukin-1 receptor type 
I, Rabbit articular chondrocytes. 
Introduct ion 
OSTEO-ARTICULAR DISEASES, either inflammatory 
(rheumatoid arthritis, RA) or degenerative (osteo- 
arthritis, OA) are accompanied by dramatic erosion 
of the art icular cartilage. There is now compelling 
evidence that interleukin-1 (IL-1) plays a key role in 
the damaging process of cartilage extracellular 
matrix [1, 2]. This cytokine promotes the secretion 
by art icular chondrocytes ofthe degrading enzymes 
collagenase and stromelysin [3, 4]. Moreover, IL-1 is 
capable of inhibiting the synthesis of both collagen 
and proteoglycans [5, 6]. The cumulative ffect of 
these processes causes a local loss of matrix which 
is so far nonreversible. While rheumatoid synovial 
pannus is supposed to be the major source of IL-1, 
in OA the cytokine may be released locally from 
indigenous chondrocytes as an episodic process, 
perhaps due to micro-inflammation r mechanical 
trauma. As chondrocytes could be activated in early 
stages of OA to synthesize new matrix [7, 8], one may 
Submitted 19 May 1994; accepted 10 February 1995. 
This work has been supported by INSERM CJF 91-06. 
Address correspondence to: Prof. J.-P. Pujol, Laboratoire de 
Biochimie du Tissu Conjonctif, Facult~ de M6decine, niveau 3, 
14032 Caen Cedex, France. 
suggest hat IL-1 likely disturbs this repair process 
of cartilage. 
Both forms of IL-1, IL-I~ and IL-1/~ exert their 
actions on cells by specific receptors which are 
widely distributed on cells of many lineages [9, 10]. 
Two IL-1 receptors (IL-1R), type I and type II, 
have been cloned from both murine and human 
sources [11-13]. Despite the relatively low extent 
of homology between IL-I~ and IL-lfl, both can 
bind to the two receptors [11, 14]. The type I recepto~ 
(80 kDa) is a membrane protein of 552 residues, 
containing a membrane spanning region, an 
extracellular ligand binding region composed of 
three immunoglobulin-like domains, and a cyto- 
plasmic region of 213 residues. The type II IL-1R 
(67 kDa) has an extracellular ligand-binding region 
similar to that of type I receptor, with three 
immunoglobulin-like domains, but has only a short 
cytoplasmic domain of 29 residues. The type I 
receptor displays ahigh-affinity binding for IL-1 and 
is capable of transmitt ing signals across the 
membrane [15] while there is no evidence at present 
that the type II receptor has a signaling function. 
Recent data suggest that when the two different IL-1 
receptors are present on the same cell they function 
independently in the ligand binding and do not form 
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a heterodimeric complex [16]. Moreover, IL-1R type 
II can inhibit IL-1 activity by acting as a decoy target 
for IL-1 [17]. 
Given the deleterious effects exerted by IL-1 on 
the homeostasis of articular cartilage, it is 
important to understand the mechanisms con- 
trolling the expression of IL-1 receptors on chondro- 
cytes and how this expression can be modulated by 
drug intervention. It has been reported that 
chondrocytes express the type I IL-1R and, in 
culture, display up to 7000 sites per cell [18-21]. Type 
II receptor has never been observed in this cell type, 
but two IL-1 binding proteins of molecular weight 
higher than type I receptor, 116 and 200 kDa, have 
been detected by affinity cross-linking in cultures of 
rabbit articular chondrocytes (RAC) [22]. Several 
recent studies have shown that growth factors were 
able to exert modulatory effects on IL-1 activity. For 
example, fibroblast growth factor (FGF) was shown 
to enhance the ability of IL-1 to induce metallo- 
protease synthesis in chondrocytes and to up-regu- 
late the expression of IL-1R in these cells [19]. On the 
other hand, we and others have demonstrated that 
transforming rowth factor-fl (TGFfl) inhibited the 
activity of IL-1 on both catabolic and anabolic levels 
[22, 23]. Furthermore, we have previously shown 
that TGFfl was also able to reduce the IL-1 binding 
of cultured rabbit articular chondrocytes by 
decreasing the number of receptors at the cell 
surface, suggesting that the opposite ffects exerted 
by TGFfl on IL-1 may involve down-regulation of 
IL-1R expression [23]. In this paper, we examined 
whether the steady state mRNA levels for type I 
IL-1R in RAC were modulated by TGFfl-1. As the 
message for IL-1R in these cells is generally too low 
to be detected by conventional hybridization 
procedures, we used reverse transcription-poly- 
merase chain reaction (RT-PCR) to estimate the 
levels of mRNA present in our cultures. 
Materials and Methods 
CYTOKINES AND GROWTH FACTORS 
Human platelet-derived TGFfl-1 was obtained 
from R&D Systems (Minneapolis, MN, U.S.A.). IL-I~ 
was a generous gift from Dr Saklatvala (Cambridge, 
U.K.). 
CHONDROCYTE CULTURE 
Chondrocytes were prepared from 3-week-old 
rabbits [24] and cultured in Dulbecco's modified 
Eagle's medium (DMEM) containing 10% heat- 
inactived fetal calf serum (FCS), at 37°C, in a 5% CO2 
environment. The experiments were performed on 
primary cultures, 7 days after seeding, when they 
had reached confluency. 
[125]-LABELED IL-I~ BINDING MEASUREMENT 
Human recombinant IL-I~ was radiolabeled using 
a chloramine-T procedure [25]. 
Confluent cultures in 10 cm 2 dishes, some treated 
with TGFfl-1 for several periods, were washed once 
with DMEM plus 1% FCS and twice with binding 
medium (DMEM, 0.1% BSA, and 25ram HEPES, 
pH7.5). Cultures were then incubated at 4°C 
with 200pM [125I]-labeled IL-la (specific activity 
..... 60pCi/pg) in l ml (final volume). Nonspecific 
binding was determined in the presence of a 100-fold 
excess of unlabeled ligand. Optimal binding of 
[125I]-labeled IL-I~ was observed at 4 h. 
At the end of incubation period, the free ligand 
was removed, and the cell layer was extensively 
washed with binding medium. The bound material 
was then extracted with 0.5 M NaOH (0.5 ml per 
dish), neutralized with 0.5 M HC1 and counted. 
RNA EXTRACTION AND PCR ANALYSIS 
The cellular level ofmRNA coding for type I IL-1R 
was estimated by analysis of PCR amplification 
products. RNA were extracted by the method of 
Cathala et al. [26]. cDNA was made from l t tg 
of total rabbit chondrocyte RNA using Superscript 
reverse transcriptase (Gibco/BRL) with antisens 
5'TCATAGGTCTTTCCATCTGAA3' (primer 2) as 
primer, following the manufacturer's instructions. 
For the PCR, olignucleotide primers sequences 
were 5'CTTTGGTTTGTTCCTGC: (primer 1) and 
3'TCATAGGTCTTTCCATCTGAA (primer 2). These 
primers correspond to the homologous olignucleo- 
tide sequence determined by comparative analysis 
of human, murine and chicken IL-1R sequences with 
the Gene Jockey program. They were synthesized 
and purified on RP1 cartridge by Genosys 
(Cambridge, U.K.). PCR was carried out for 35 cycles 
in a total volume of 100/d containing 67mM 
Tris-HC1 pH 8.8, 16 mM (NH4)2SO4, 1.25 hiM MgC12, 
0.01% Tween 20, 200 #M dNTPs, 1.5 units of Taq 
polymerase (Eurobio, France) and 25 pmol of each 
primer. Total synthesized DNA was analysed on a 
0.8% agarose gel containing Tris Borate/EDTA and 
ethidium bromide. PCR amplification products were 
visualized by U.V. light transillumination. 
PCR QUANTIF ICATION 
For the quantification, three methods were 
used on different independent experiments. First, 
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we evaluated the TGFfl effect by scanning the 
ethidium bromide signals. Second, we determined 
the level of type I IL-1R mRNA by hybridization 
using the rabbit 900-bp DNA fragment (fragment 
synthesized between primer 1 and primer 2) as 
a probe. Briefly, the gel was treated 30 min in a 
denaturation solution (1.5 M NaC1, 0.5 M NaOH) and 
neutralized for 30min in 3M Na acetate 
pH 5.5. Transfer was performed on nylon membrane 
(PallBiodyne) which was then pre-hybridized for 
12h and hybridized overnight at 42°C in hy- 
bridization buffer (50% formamide, 5 × Denhart, 
5xSSC, 0.1% SDS and 0.1mg/ml salmon DNA 
sperm) with the rabbit IL-1RI probe (900-bp 
fragment) labelled using Megaprime Amersham kit 
(specific activity: 109 dpm/pg). The membrane was 
washed three times in 2× SSC + 0.1% SDS: 30 rain at 
room temperature, 15min at 42°C and 5 min at 60°C. 
This technique also provided a means to check the 
specificity of the PCR products. The specificity of 
our 900-bp fragment probe was first verified by 
sequencing. 
A more quantitative method was developed in 
which dNTP were present at 20 pM and [~:~P]-dCTP 
(3/~Ci) was added. Aliquots of 5pl were taken from 
the reaction at different numbers of cycles (n), after 
having determined the exponential phase of the 
assay, and loaded on a 0.8% agarose gels stained 
with ethidium bromide. In order to facilitate 
location of the band, especially in early cycles, 
unlabeled PCR products were added to the gel 
loading buffer. The single 900-bp band was cut out 
from the gel, slices were denatured with 0.5 ml of 6 M 
NaI at 55°C during 10 min in liquid scintil lation 
vials and the radioactivity incorporated in the 
product was counted. 
Concent rat ion  of the 900-bp band (mol/pl) 
produced in different numbers of cycles was 
calculated from the incorporated radioactivity 
(cpm/lll), the specific activity of the precursor dCTP 
(cpm/pl) determined in 5 pl of the reaction mixture 
and the number of cytosin moieties in the product, 
according to the formula: 
cpm/td 
mol/gl = cpm/mol × 138" 
The initial concentration of cDNA at cycle zero, N,~ 
(mol/pl), and the efficiency of amplification, 'eft', 
was determined by l inear regression analysis of the 
transformed equation describing product accumu- 
lation in PCR [27], 
log N,, = log eft× n + log No. 
SEQUENCING 
Two DNA strands from the 900-bp fragment 
were sequenced respectively from primer 1 and 2 
using the 'ds DNA cycle sequencing system' 
(Gibco/BRL). The two sequences obtained were 
< 900 bp 
< 700bp 
< 500 bp 
28 S 
C TGF 
~ <  , 900 bp 
FIG.-~t': PCR analysis o f  IL-1RI transcripts in RAC. 
Confluent cells in 75 cm 2 flasks were treated for 3 days 
with or without TGFfl (2.5 ng/ml) and total RNA was 
extracted. PCR reaction was carried out with I pg of total 
RNA. Ethidium bromide staining of agarose electro- 
phoretic gel shows the presence of a 900-bp fragment 
corresponding to the expected segment. The PCR 
products were run on 0.8% agarose gels, capillary blotted 
onto nylon membranes and hybridized with [32P]-labeled 
rabbit IL-1RI probe using high stringent conditions (42°C, 
50% formamide). The expected fragment of about 900 bp 
is indicated (inset). The relative amounts of each signal 
was determined by scanning the bands. Ethidium bromide 
staining of the 28 S RNA was used to check the loading 
of RNA samples used for PCR amplification. 
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rab CCGTTGCTGGAGATGGAGGACTTGTGTGCCCTTACATGGA TTTTTTCAAA 
hum CCGTTGCAGGAGACGGAGGACTTGTGTGCCCTTATATGGAGTTTTTTAAAA 
3 
rab GAAAGFAGATTTTATGTATATCCATTTATTTGTTTAGCCAAGAACACA 
hum GAAAGTAGATTTTATAAACATCCATTTACCTGTTTTGCCAAGAATACA 
FIG. 2. Specificity for IL-1RI of a 900-bp fragment, deduced from comparison between human and rabbit sequences. The 
900-bp PCR product obtained from rabbit mRNA was sequenced by primer extension from both ends and compared with 
human IL-1RI (h IL-1RI) sequence. Two parts of that sequence ([]) are indicated with the homology degree (-) (90%). 
compared with human [12] and mur ine [13] IL-1R 
type I sequences using the Gene Jockey program. 
Results and Discuss ion 
Connective t issue cells, such as dermal  f ibroblast, 
synovial  cells and ar t icu lar  chondrocytes  have been 
reported to express low numbers  of IL-1 receptors,  
compared with lymphocytes or T lymphoma cell 
l ines [28, 29]. The specific mRNA signal  encoding 
the receptor  is also general ly  expressed at low level 
in most  of these cell types so that  it is somet imes 
barely detectable by hybr id izat ion of Nor thern  
blotting. To study the regulat ion  of the expression 
of IL-1R in rabbit  a r t i cu la r  chondrocytes,  we 
therefore used ampl i f icat ion of the message by 
reverse t ranscr iptase-po lymerase chain react ion  
(RT-PCR). In addit ion to the widely expressed type 
I receptor  for IL-1, another  b inding prote in (type I I  
receptor)  has been character ized in some cells 
be longing to the B cell types [11]. However, only type 
I receptor  of IL-1 has been so far detected in most  of 
the connect ive t issue cells, including rabbit  
a r t i cu la r  chondrocytes [22]. 
As the sequence of rabbit  IL-1RI gene has not yet 
been establ ished, we compared  the publ ished cDNA 
FIG. 3. Effect of TGFfl-1 on the expression of IL-1RI in RAC. (a) Detection of PCR product by ethidium bromide staining. 
(i) Confluent cells in 75 cm 2 flasks were treated for different periods with or without TGFfl (2.5 ng/ml), cDNA obtained 
from RAC total RNA (1 pg) were amplified by RT-PCR for 35 cycles (see 'Materials and Methods'). The PCR products were 
electrophoresed on0.8% ethidium bromide-stained agarose gels. The relative amounts of each signal was determined by 
scanning the bands. (ii) Ethidium bromide staining of the 28 S RNA was used to check the loading of RNA samples used 
for PCR amplification. (b) [I~sI]-IL-1 binding was measured in RAC (seeded in 9.6 cm '2 dishes and grown to confluency) 
incubated with (g~b) or without ( J )  2.5 ng/ml TGFfl-1. Cells were rinsed once with 1% FCS-containing DMEM and twice 
with binding medium, treated with [125I]-IL-1 (2.00 pM) for 4 h at 4°C (with gentle shaking) and bound radioactivity was 
determined by extracting the cell layer with 0.5 M NaOH. Specific binding in control and TGFfl-treated cells was 
calculated by subtracting from the total binding the amount of binding in the presence of a 100-fold excess of unlabeled 
ligand. Values are the mean +_ S.D. of three determinations from independent experiments performed on different cultures. 
Student's t-test was used to evaluate the differences between the means of each group. **, P < 0.01 vs control; NS = non 
significant vs control. 
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sequences for human [12], murine [13] and chicken 
[30] in order to determine zones of high homology 
which could be used to select primers capable of 
recognizing the rabbit type I receptor mRNA. Two 
primers of 17 and 21 nucleotides, corresponding 
respectively to positions 323 (sens) and 1240 
(antisense) of the human cDNA II-lR type I gene, 
were synthesized and used in primer-extension 
analysis with total mRNA from monolayer cultures 
of RAC. After amplification, we obtained a band of 
approximately 900 bp which corresponds to the size 
of the expected PCR product (Fig. 1). Two additional 
700-bp and 500-bp faint bands were visible on the gel. 
One (700 bp) was further shown to be nonspecific of 
IL-1RI mRNA using hybridization with a specific 
cDNA probe prepared from the 900-bp fragment (see 
later). The other band (500 bp) hybridized with 
this probe (not shown), suggesting that this 
fragment coul'd result from a differential splicing, as 
reported in some recent papers [31, 32]. Sequencing 
of this fragment is presently undertaken i order to 
check its specificity. 
To confirm the specifity of the 900-bp product was 
obtained by PCR, we sequenced this fragment from 
both ends, using ds DNA cycle sequencing system. 
Comparison of two 50-nucleotide fragments with the 
corresponding human sequence revealed 90% 
homology (Fig. 2). Therefore, this 900-bp PCR 
product was considered as sufficiently specific to 
prepare a cDNA probe which could be used in 
further investigation on the influence of TGFfl on 
II-1RI gene expression in RAC. 
We have previously demonstrated that binding of 
radiolabelled IL-1 was inhibited by TGFfl in RAC 
cultures incubated for 72 h [23]. Thus, we first 
determined for the same time period the level of IL-1 
R type I mRNA. As shown in Figs 1, 3 and 4, the 
900-bp PCR product was dramatically reduced 
under the effect of TGFfl. This data is consistent 
with a previous report demonstrating byScatchard 
1E-14 
1E-14 
8E-15 
6E-15 
~ e  o Control 
. TGF-B 
4E-15 I I I I t 
12 14 16 18 20 22 24 
Cycles 
eft 
N1 × 1015 
(mol/gl) 
Control (%) 
1 h 48h 
C TGFfi C TGFfl 
1.064 1.057 1.066 1.068 
2.306 3.508 2.804 2.278 
100 152 100 80 
Fro. 4. Accumulation of product in PCR. Confluent cells were treated for 2 days with or without TGFfl (2.5 ng/ml) and 
total RNA was extracted. PCR reaction in the presence of [32P]-dCTP was carried out as described in Materials and 
Methods with I gg of total RNA. Plot of product accumulation (mol/#l) vs cycle number are represented. The equations 
illustrate how the number of target molecules, 'No' and the efficiency of amplification, 'eft', are calculated by linear 
regression from the transformed quation describing product accumulation during the PCR (see Materials and Methods). 
Inset shows the effect of TGFfl in percentage compared with control for 1-h and 48-h incubation periods. 
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FIG. 5. Effect of TGFfl on the stability of IL-1RI mRNA. (a) RAC were incubated in the presence (O) or absence (Q) of 
TGFfl (2.5 ng/ml) for 66 h. Then actinomycin D (5 pg/ml) was added to inhibit transcription. At various times after 
actinomycin D additi.on, total RNA was extracted and RT-PCR reaction was carried out as described in Materials and 
Methods. PCR products were hybridized with specific probe and densitometric analysis was performed. (b) Decay profiles 
of IL-1RI mRNA levels. 
analysis that the number of IL-1R type I was reduced 
by TGFfl in RAC [22]. It also indicates for the first 
time that this effect involves the transcriptional 
level. However, the present work reveals that TGFfl 
does not exert the same effect on the IL-1RI mRNA 
expression i  the early times of exposure. Indeed, as 
shown in Fig. 3 for the time 1 h, the factor induced 
an increase of the PCR product corresponding to 
IL-1RI mRNA. In such experiments the d crease of 
IL-1R expression was shown to begin after 48 h 
incubation with TGFfl 2.5 ng/ml. Similar results 
were obtained in other experiments using RT-PCR 
and hybridization of the PCR products with the 
900-bp IL-1R probe. An increase of the PCR product 
was observed after 1 h incubation with TGFfi 
whereas inhibition was present at 48 and 72 h (see 
Fig. 1 for the 72 h period). To improve the PCR 
quantification, we used a more quantitative 
protocol. PCR was performed in the presence of 
[:~2P]-dCTP as described in Materials and Methods. 
The results confirmed the differential effect of TGFfi 
on IL:IR type I expression: a 50% augmentation 
after 1 h incubation followed by a decrease of 20% 
after 48 h (Fig. 4). To determine whether 72 h 
incubation with TGFfl could decrease the IL-1R 
mRNA stability, we blocked the transcript ion of the 
gene by addition of actinomycin D (5 pg/ml) and 
studied by RT-PCR the decay of the IL-1R expression 
with time (Fig. 5): Unstimulated cells showed an 
IL-1R mRNA half-life of approximately 4 h. This 
value is consistent with data reported already 
showing that T lymphocytes display half-lives in the 
same range [33]. As expected, the mRNA level was 
lower in TGFfl-treated cultures at the first time 
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point following actinomycin blockage, but the decay 
rate was then similar to that of the control, as judged 
by the slope in each case. This suggests that 
decreased steady-state amounts of IL-1RI observed 
under TGFfl treatment resulted from a diminution 
in gene transcription activity rather than from 
stability of the mRNA. To this regard, it is 
interesting to note that specific cis-acting regions, 
including a SP1 site and G + C enriched zones, have 
been characterized recently in the promoter of 
human IL-1RI [32]. These sequences are susceptible 
to bind transcription factors which could be 
modulated by growth factors. 
These results indicate that TGFfi may modulate 
the IL-1RI gene expression of RAC by a differential 
mechanism which could be time dependent. 
However, the early TGFfl-induced increase in 
mRNA is not accompanied by a correlated increase 
of the receptor synthesis (Fig. 3). It is also surprising 
that a marked ecrease of IL-1 binding was observed 
after a 24h incubation with TGFfl while no 
significant inhibition occurred at the mRNA level. 
As an explanation for that finding, we suggest hat 
during this time period, the factor could exert its 
effect mainly through inhibition of mRNA trans- 
lation. Such a transcriptional control has been 
reported already for IL-1 effect on IL-1R expression 
in osteoblasts [34]. Whatever the mechanism, it is 
clear that this first period of TGFfl action contrasts 
with the following times (48, 72h) where a 
correlation is well established between the reduced 
level of mRNA coding for IL-1R and that of the 
corresponding binding at the surface. 
Our findings demonstrate hat the expression of 
IL-1RI on the cell surface of art icular chondrocytes 
could be down-regulated by TGFfl-1 at the 
pre-translational level. This mechanism may ac- 
count for the antagonism exerted by TGFfl on most 
of the IL-l-induced effects, including degradation 
of matrix cartilage and inhibition of matrix 
synthesis. It is possible that this effect of TGFfl 
implicates signaling pathways which are so far 
unknown. For example, TGFfl has been shown to 
inhibit the production of nitric oxide (NO), a widely 
spread messenger with deleterious effects which is 
produced in great amounts under IL-1 treatment 
[35]. It is also becoming clear that other cytokines 
could interact to modulate the IL-1RI expression. To 
this end, bFGF has been described as a stimulant of 
IL-1RI expression i  RAC [19]. Thus, the number of 
IL-1 receptors on art icular chondrocytes is likely to 
depend on a cytokine network which probably 
changes w i th  the physiopathological state of 
cartilage. 
It is not yet known how the pattern of IL-1RI 
expression in art icular chondrocytes may be 
relevant to the osteoarthrit ic process. However, our 
studies uggest that TGFfl could be released from its 
matrix reservoirs or produced by the chondrocytes 
during the early stages of the disease and could 
contribute to the repair of cartilage as a protective 
agent against IL-1 effects. Further studies aimed at 
determining the levels of TGFfl and those of IL-1RI 
in cartilage from experimental osteoarthrit ic 
animals will provide further insight into the 
mechanism of IL-1RI expression i altered cartilage. 
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